Monoclonal Antibodies which Identify the Glycoprotein carrying the CA125 Epitope

Application: An immunoassay for the detection of CA125 utilizing the monoclonal antibodies

CA125 is an antigenic determinant located on the surface of ovarian carcinoma cells and elevated in the serum of greater than 90% of patients with carcinoma. This invention provides hybridomally produced monoclonal antibodies that are specifically immunoreactive with the glycoprotein carrying the CA125 epitope. Researchers have demonstrated that the monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the extracellular matrix of CA125 producing cells.

This invention employs the monoclonal antibodies to improve the assay and immunohistologic detection of the CA125 antigen. Since the antibodies recognize the cell surface component of tumor cells, it is further anticipated that the antibodies would provide a means of delivering imaging isotopes and chemotherapeutic agents to tumor cells, thereby enhancing the diagnosis and treatment of neoplasms. Reference: - U.S. Patent # 5,976,818

- "New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope", Am. J Obstet Gynecol, December 1991

- "Distribution of CA125 in embryonic tissues and adult derivatives of the fetal periderm", Hardardottir, et al, Am. J Obstet Gynecol, 1990; 163: 1925-31

92-01

Patent Status: Issued U.S Patent #5,976,818

Licensing Status:  Available for Exclusive Licensing

Licensing Partner to commercialize that and other related technologies